3 completed, 3 unknown, 2 recruiting, 1 terminated. 9 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 3, Unknown 3, Recruiting 2, Terminated 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Infectious Disease: new trials by email Literature Review of Infectious Disease trials Research Report on Infectious Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial genotype-directed dosing with dosing software based on therapeutic drug monitoring - Fungal Infection, Haematological Malignancy | Phase 2 | Recruiting | The University of Queensland | 104 | 2025-04-14 | 2026-04-16 |
| Rickettsia Clearance Study Doxycyclin, Azithromycin - Infectious Disease, Therapeutics | Phase 2 / Phase 3 | Recruiting | Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit | 72 | 2024-11-01 | 2026-10-13 |
| A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression Tafenoquine Oral Tablet, Placebo - COVID 19 Disease, Mild to Moderate COVID 19 Disease | Phase 2 | Unknown | 60P Australia Pty Ltd | 148 | 2023-08-01 | 2023-07-17 |
| Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals RVM-V001 30 µg, RVM-V002 30 µg, RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration - Infectious Disease, COVID-19 | Phase 1 / Phase 2 | Terminated | RVAC Medicines (US), Inc. | 24 | 2023-03-22 | 2023-10-16 |
| An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity Stamaril, Imojev, Ixiaro - Infectious Disease, Yellow Fever | Phase 2 | Unknown | Singapore General Hospital | 70 | 2022-09-28 | 2023-04-12 |
| University of Utah COVID-19 Hydrochloroquine Trial Hydroxychloroquine, Placebo oral tablet - Coronavirus Infection, Coronavirus | Phase 2 | Completed | University of Utah | 368 | 2020-04-04 | 2023-02-15 |
| Phase 2, Multiple Ascending Dose Proof of Concept Study CMX157, TDF - Infectious Disease | Phase 2 | Completed | ContraVir Pharmaceuticals, Inc. | 62 | 2016-05-01 | 2017-09-13 |
| A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers NU300, ActHIB, Prevnar 13 - Infectious Disease | Phase 2 | Unknown | Nuron Biotech Inc. | 220 | 2013-03-01 | 2013-09-23 |
| Safety & Efficacy of an Antibacterial Protein Molecule Applied Topically to the Nostrils of Volunteers and Patients P128-0.1 mg, P128-0.3 mg, P128-1.0 mg - Infectious Disease, Bacterial Infections | Phase 1 / Phase 2 | Completed | GangaGen, Inc. | 74 | 2012-12-01 | 2016-03-07 |
Communicable Diseases (9) · COVID-19 (2) · Bacterial Infections (1) · Coronavirus Infections (1) · Encephalitis, Japanese (1) · Hematologic Neoplasms (1) · Hepatitis B, Chronic (1) · Infections (1) · Mycoses (1) · Neoplasms (1) · Scrub Typhus (1) · Typhus, Endemic Flea-Borne (1) · Virus Diseases (1) · Yellow Fever (1)
Disease Attributes (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Infections (8) · Bacterial Infections and Mycoses (3) · RNA Virus Infections (3) · Virus Diseases (3) · Coronaviridae Infections (2) · Lung Diseases (2) · Nidovirales Infections (2) · Pneumonia (2) · Pneumonia, Viral (2) · Respiratory Tract Diseases (2) · Respiratory Tract Infections (2) · Vector Borne Diseases (2)
13-valent pneumococcal vaccine (1) · Azithromycin (1) · Doxycycline (1) · Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (1) · Hydroxychloroquine (1) · RVM-V001 COVID-19 vaccine (1) · hexadecyloxypropyl 9-(2-(phosphonomethoxy)propyl)adenine (1) · tafenoquine (1)
60P Australia Pty Ltd (1) · ContraVir Pharmaceuticals, Inc. (1) · GangaGen, Inc. (1) · Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit (1) · Nuron Biotech Inc. (1) · RVAC Medicines (US), Inc. (1) · Singapore General Hospital (1) · The University of Queensland (1) · University of Utah (1)
Singapore (3) · United States (3) · Australia (1) · Laos (1) · Thailand (1)
Adam Spivak, MD (1) · Dale A Fisher, MBBS, FRACP (1) · Jason A Roberts, PhD (1) · John Sullivan-Boylai, MD (1) · Shirin Kalimuddin, MRCP (UK) (1) · Surinder Kher, MD (1) · Weerawat Phuklia, PhD (1)
PMID 30519584, PMID 32382733, PMID 33333292, PMID 33820486, PMID 35101449, PMID 35668841, PMID 35713893, PMID 36969244, PMID 39794472, PMID 9598455